A detailed history of Nuveen Asset Management, LLC transactions in Alx Oncology Holdings Inc stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 105,894 shares of ALXO stock, worth $171,548. This represents 0.0% of its overall portfolio holdings.

Number of Shares
105,894
Previous 105,894 -0.0%
Holding current value
$171,548
Previous $638,000 69.91%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$4.81 - $15.38 $87,739 - $280,546
18,241 Added 20.81%
105,894 $1.58 Million
Q3 2023

Nov 14, 2023

SELL
$4.19 - $7.35 $43,622 - $76,520
-10,411 Reduced 10.62%
87,653 $420,000
Q1 2023

May 15, 2023

SELL
$4.52 - $11.71 $31,644 - $81,981
-7,001 Reduced 6.66%
98,064 $443,000
Q4 2022

Feb 14, 2023

SELL
$9.51 - $12.95 $100,387 - $136,700
-10,556 Reduced 9.13%
105,065 $1.18 Million
Q3 2022

Nov 14, 2022

SELL
$8.23 - $15.14 $9,859 - $18,137
-1,198 Reduced 1.03%
115,621 $1.11 Million
Q2 2022

Aug 15, 2022

BUY
$5.89 - $19.46 $401,656 - $1.33 Million
68,193 Added 140.24%
116,819 $945,000
Q1 2022

May 16, 2022

SELL
$13.65 - $22.06 $207,889 - $335,973
-15,230 Reduced 23.85%
48,626 $872,000
Q4 2021

Feb 14, 2022

SELL
$21.49 - $74.4 $28,560 - $98,877
-1,329 Reduced 2.04%
63,856 $1.37 Million
Q3 2021

Nov 12, 2021

SELL
$52.51 - $80.91 $1.56 Million - $2.41 Million
-29,752 Reduced 31.34%
65,185 $4.81 Million
Q2 2021

Aug 16, 2021

BUY
$52.2 - $75.23 $436,339 - $628,847
8,359 Added 9.65%
94,937 $5.19 Million
Q1 2021

May 17, 2021

BUY
$62.84 - $87.68 $2.49 Million - $3.48 Million
39,673 Added 84.58%
86,578 $6.39 Million
Q4 2020

Feb 16, 2021

BUY
$34.11 - $112.26 $375,107 - $1.23 Million
10,997 Added 30.63%
46,905 $4.04 Million
Q3 2020

Nov 16, 2020

BUY
$29.36 - $47.1 $1.05 Million - $1.69 Million
35,908 New
35,908 $1.36 Million

Others Institutions Holding ALXO

About ALX ONCOLOGY HOLDINGS INC


  • Ticker ALXO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,747,100
  • Market Cap $66M
  • Description
  • ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...
More about ALXO
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.